NBIX
NASDAQNeurocrine Biosciences Inc.
News · 26 weeks87-77%
2026-03-012026-08-23
Mix4690d
- Insider25(54%)
- Other11(24%)
- SEC Filings5(11%)
- Earnings2(4%)
- Leadership2(4%)
- Analyst1(2%)
Latest news
25 items- PRNeurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive DyskinesiaINGREZZA is the only vesicular monoamine transporter 2 inhibitor with clinical trial data demonstrating improvements in quality of life and functionality in people living with tardive dyskinesia across multiple validated patient-reported outcomesMean improvements in the patient-reported impacts of tardive dyskinesia and clinician-rated movement severity exceeded established thresholds for clinically meaningful change at Week 24, with improvements observed regardless of underlying psychiatric diagnosis or baseline movement severityApproximately 58% of patients met the threshold for tardive dyskinesia symptomatic remission at Week 24, based on clinician assessment of movement severityFindings
- PRNeurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple AgonistInitiation of study marks an important milestone in advancing Neurocrine's obesity portfolio and investigational metabolic disease pipeline SAN DIEGO, Aug. 7, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the initiation of a Phase 1 first-in-human clinical study evaluating the safety and tolerability of NBIP-'1968, an investigational GLP-1/GIP/glucagon receptor triple agonist being developed as a therapy for obesity. "Obesity is a complex chronic disease driven by multiple biological pathways, underscoring the need for additional treatment options," said Sanjay Keswani, M.D., Chief Medical Off
- INSIDERChief Scientific Officer Onyia Jude gifted 2,409 shares, decreasing direct ownership by 10% to 20,996 units (SEC Form 4)4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
- SECSEC Form S-8 filed by Neurocrine Biosciences Inc.S-8 - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)
- SECAmendment: Neurocrine Biosciences Inc. filed SEC Form 8-K: Financial Statements and Exhibits8-K/A - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)
- SECSEC Form 10-Q filed by Neurocrine Biosciences Inc.10-Q - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)
- INSIDERDirector Norwalk Leslie V sold $227,508 worth of shares (1,250 units at $182.01) as part of a pre-agreed trading plan and exercised 842 shares at a strike of $139.43, decreasing direct ownership by 14% to 2,430 units (SEC Form 4)4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
- SECNeurocrine Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)
- PRNeurocrine Biosciences Reports Second-Quarter 2026 Financial ResultsTotal Second-Quarter 2026 Revenue Grew 39% Year-Over-Year to $959 MillionINGREZZA® (valbenazine) 2026 Net Sales Guidance Raised to $2.825 to $2.875 BillionAcquisition of Soleno Therapeutics Completed in May 2026SAN DIEGO, July 30, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the second quarter ended June 30, 2026. "Our second quarter performance demonstrates the power of a strategy designed to compound over time," said Kyle W. Gano, Ph.D., Chief Executive Officer of Neurocrine Biosciences. "As our commercial portfolio of first-in-class medicines continues to grow, so
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Neurocrine Biosciences Inc.SCHEDULE 13G/A - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)
- PRNeurocrine Biosciences Announces Key Leadership Hiring, PromotionsSAN DIEGO, July 23, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the appointment of three Senior Vice Presidents, further strengthening its leadership team as the company executes its next phase of growth, expands its commercial portfolio and advances one of the industry's strongest neuroscience pipelines. These appointments reflect Neurocrine's continued evolution into a diversified, multi-product biopharmaceutical company positioned to deliver sustainable long-term growth. The appointments include Bret Paulson, who joins the company as Senior Vice President, Market Access, and the promotions
- PRNeurocrine Biosciences Appoints Samir Siddhanti Chief Business OfficerSAN DIEGO, July 21, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the appointment of Samir Siddhanti as Chief Business Officer and a member of the company's executive Management Committee. As Chief Business Officer, Siddhanti will lead Neurocrine's enterprise growth strategy, overseeing business development, corporate strategy, alliance management and program management to maximize the value of the company's expanding pipeline through both internal innovation and strategic external opportunities.Since joining Neurocrine in 2017, Siddhanti has assumed leadership roles of increasing responsibilit
- INSIDERChief Regulatory Officer Delaet Ingrid exercised 4,367 shares at a strike of $106.02 and sold $790,514 worth of shares (4,367 units at $181.02) as part of a pre-agreed trading plan (SEC Form 4)4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
- INSIDERChief Legal Officer Lippoldt Darin exercised 10,000 shares at a strike of $81.49 and sold $1,796,014 worth of shares (10,000 units at $179.60) as part of a pre-agreed trading plan (SEC Form 4)4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
- INSIDERChief Regulatory Officer Delaet Ingrid exercised 14,571 shares at a strike of $103.52 and sold $2,603,112 worth of shares (14,571 units at $178.65) as part of a pre-agreed trading plan (SEC Form 4)4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
- PRNeurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial ResultsConference Call and Webcast Scheduled for Thursday, July 30SAN DIEGO, July 9, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced today that it has scheduled its second quarter 2026 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on July 30, 2026. The schedule for the press release and conference call / webcast is as follows:Q2 2026 Press Release: July 30, 2026 at 1:00 p.m. PT / 4:00 p.m. ETQ2 2026 Conference Call: July 30, 2026 at 1:30 p.m. PT / 4:30 p.m. ETDomestic Dial-In Number: 800-347-6865International Dial-In Number: 203-518-9757Conference ID: NBIXTh
- PRNeurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal HyperplasiaSAN DIEGO, July 1, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the initiation of its Phase 2 clinical study to assess the safety and tolerability of crinecerfont in children aged 3 months to under 4 years with classic congenital adrenal hyperplasia (CAH). Crinecerfont, marketed as CRENESSITY®, is approved in the United States as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients 4 years of age and older with classic CAH. "Infants and young children with classic CAH face significant health
- INSIDERChief Legal Officer Lippoldt Darin exercised 10,000 shares at a strike of $81.49 and sold $1,701,492 worth of shares (10,000 units at $170.15) as part of a pre-agreed trading plan (SEC Form 4)4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
- PRSoleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal PeriodParticipants who resumed VYKAT XR following a 16-week randomized withdrawal period demonstrated improvements in hyperphagia and behavioral symptoms as early as Week 13, with benefits continuing through 2 yearsVYKAT XR demonstrated statistically significant and sustained improvements in hyperphagia and Prader-Willi syndrome-related behaviors for up to 3 years compared to real-world data from the PATH for PWS Natural History StudySAN DIEGO, June 15, 2026 /PRNewswire/ -- Soleno Therapeutics, a Neurocrine Biosciences (NASDAQ:NBIX) company, today announced late-breaking data at ENDO 2026 showing that resuming treatment with VYKAT® XR (diazoxide choline) extended-release tablets for two years afte
- PRNeurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026Androstenedione and other adrenal hormone levels in 11β‑hydroxylase-deficient patients improved substantially after initiation of CRENESSITY, with >90% median reductions in 11-deoxycortisol and 11-deoxycorticosteroneNearly all patients (14/15) reduced their total glucocorticoid dose with CRENESSITY, and 2 of 5 patients on antihypertensive medications reduced or discontinued these drugsFindings provide initial clinical insights in patients with classic congenital adrenal hyperplasia due to 11β-hydroxylase deficiency, a rare subtype not previously studied in clinical trials of CRENESSITYSAN DIEGO, June 15, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced clinical
- PRNeurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026Two-year data showed that pediatric patients with accelerated bone age at baseline experienced slowed bone age progression and improved predicted adult height with CRENESSITYCross-sectional caregiver survey data showed universal satisfaction with CRENESSITY, willingness to recommend treatment and increased optimism about their child's future quality of life following treatment initiationSAN DIEGO, June 15, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced new two-year data from the Phase 3 CAHtalyst® Pediatric study showing positive growth outcomes in children and adolescents with classic congenital adrenal hyperplasia treated with CRENESSITY® (crinecerfont). Pa
- PRNeurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026Two-year CRENESSITY data in adults showed improvements in cardiometabolic outcomes of insulin resistance, body composition and body weight alongside sustained reductions in glucocorticoid doseAmong participants who were overweight or obese at baseline, 37% achieved >5% reduction in body weight at 2 years, and 43% of those with insulin resistance at baseline were no longer insulin resistant at 2 yearsFavorable trends in bone health outcomes were observed with CRENESSITY treatment, including improvements in bone mineral density with up to 2 years of treatmentPatient‑reported survey data from adults in the open-label extension suggested improvements in quality of life outcomes and treatment sat
- INSIDERDirector Sherwin Stephen A exercised 25,000 shares at a strike of $64.10 and sold $4,132,969 worth of shares (25,000 units at $165.32) as part of a pre-agreed trading plan (SEC Form 4)4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
- INSIDERChief Scientific Officer Onyia Jude gifted 2,441 shares, decreasing direct ownership by 9% to 23,405 units (SEC Form 4)4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
- INSIDERDirector Norwalk Leslie V sold $210,072 worth of shares (1,250 units at $168.06) as part of a pre-agreed trading plan, decreasing direct ownership by 31% to 2,838 units (SEC Form 4)4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
NBIX FAQ
7 questionsWhat does Neurocrine Biosciences Inc. do?
Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric-based diseases and disorders in the United States. The company offers INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia; ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for the treatment of endometriosis pain; and ORIAHNN, a...Where does NBIX stock trade?
Neurocrine Biosciences Inc. (NBIX) is listed on NASDAQ.What sector and industry is NBIX in?
Neurocrine Biosciences Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Neurocrine Biosciences Inc. go public?
Neurocrine Biosciences Inc. (NBIX) completed its IPO in 1996.What are analysts saying about NBIX?
Neurocrine Biosciences Inc. has had 8 recent analyst actions on file. The most recent action was from Goldman: Buy on 2026-06-02.What companies are similar to NBIX?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare NBIX side-by-side with any of them on Quantisnow.How can I track NBIX on Quantisnow?
Quantisnow aggregates Neurocrine Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NBIX to receive live email and push alerts on every new disclosure.